5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

Barresi, Valeria; Grosso, Maddalena; Vitarelli, Enrica; Tuccari, Giovanni; Barresi, G

doi:10.1007/s10350-007-0311-9

Cited by 20 publications

(17 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained in a study examining 12-LO mRNA levels between breast cancer tissue and matched normal tissue, and additionally 12-LO levels were found to correlate with tumour staging [24]. Similar to 12-LO, 5-LO is reportedly overexpressed in a number of cancer tissues including prostate, renal, breast, colorectal and pancreatic tumours compared to normal tissues [25,26,27,28,29]. A number of pharmacological inhibitory studies have also indicated a regulatory role of 5-LO in cancer cell proliferation and growth [25,30,31].…”

Section: Introductionsupporting

confidence: 74%

“…In a study of colon adenomas ( n = 111), 5-LO expression was found to correlate with typical high risk factors for malignant transformation to colorectal adenocarcinoma, suggesting its usefulness as a biomarker in early detection of this cancer type [58]. Additionally, in a small study of 55 sporadic colorectal adenocarcinomas, a positive correlation of 5-LO was found with tumour stage and lymph node metastasis [29]. …”

Section: 5-lipoxygenase Pathway In Cancermentioning

confidence: 99%

See 1 more Smart Citation

Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway

Moore

Pidgeon

2017

IJMS

View full text Add to dashboard Cite

5-lipoxygenase is an enzyme responsible for the synthesis of a range of bioactive lipids signalling molecules known collectively as eicosanoids. 5-lipoxygenase metabolites such as 5-hydroxyeicosatetraenoic acid (5-HETE) and a number of leukotrienes are mostly derived from arachidonic acid and have been shown to be lipid mediators of inflammation in different pathological states including cancer. Upregulated 5-lipoxygenase expression and metabolite production is found in a number of cancer types and has been shown to be associated with increased tumorigenesis. 5-lipoxygenase activity is present in a number of diverse cell types of the immune system and connective tissue. In this review, we discuss potential routes through which cancer cells may utilise the 5-lipoxygenase pathway to interact with the tumour microenvironment during the development and progression of a tumour. Furthermore, immune-derived 5-lipoxygenase signalling can drive both pro- and anti-tumour effects depending on the immune cell subtype and an overview of evidence for these opposing effects is presented.

show abstract

Section: Introductionsupporting

confidence: 74%

Section: 5-lipoxygenase Pathway In Cancermentioning

confidence: 99%

Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway

Moore

Pidgeon

2017

IJMS

View full text Add to dashboard Cite

show abstract

“…These scores have been referred to in several published reports. ( 19–21 ) The sum of the intensity and percentage counts was used as the final score. Tumor COX‐2 expression was analyzed both qualitatively and quantitatively.…”

mentioning

confidence: 99%

Matrix metalloproteinase‐2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer

et al. 2009

View full text Add to dashboard Cite

For patients with stage II colon cancer, the usefulness of adjuvant chemotherapy remains controversial. Therefore, it is important to identify high-risk indicators. The biological prognostic factors for recurrence might allow further insight into the optimal treatment strategy for patients with node-negative disease. Matrix metalloproteinase-2 seems to be one of the essential factors for tumor invasion and lymph node metastasis. In this study, we analyzed the expression of cyclooxygenase-2 and matrix metalloproteinase-2 by immunohistochemical staining in 109 patients with stage II colon cancer. A positive correlation was observed between tumor cyclooxygenase-2 and tumor matrix metalloproteinase-2 expression (P = 0.0006) and between tumor cyclooxygenase-2 and stromal matrix metalloproteinase-2 expression (P < 0.0001). Stromal matrix metalloproteinase-2 expression was associated with disease-free survival (P = 0.0095) and was shown to be an independent risk factor for recurrence by multivariate analysis. In addition, we carried out an invasion assay in vitro to investigate whether cyclooxygenase-2 and matrix metalloproteinase-2 affected the tumor-invasive potential of colon cancer cell lines. The invasion assay showed that every cancer cell line acquired invasive potential in coculture with stromal cell lines and the cyclooxygenase-2 inhibitor suppressed this phenomenon by downregulating the matrix metalloproteinase-2 expression of stromal cells. In conclusion, these findings suggest that matrix metalloproteinase-2 expression in stromal cells can be a high-risk indicator for recurrence in patients with stage II colon cancer. (Cancer Sci 2009; 100: 852-858)

show abstract

“…From animal models and in vitro studies, it is evident that expression of 5-LOX appears to be occasionally up-regulated during neoplastic transformation [59]. Expression of 5-LOX is characterized in early stage of colon carcinogenesis and is up-regulation of 5-LOX in colonic adenomatous polyps and CRC [60,61]. These observations suggest that 5-LOX plays a role in CRC development and may be an early target for chemoprevention of CRC.…”

Section: Loxmentioning

confidence: 96%

Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets

Yasui¹,

Kim²,

Oyama³

et al. 2009

CEI

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the fourth most common cancer in the world. If detected at an early stage, treatment often might lead to cure. Of course prevention is better than cure. Epidemiological studies reveal that having a healthy diet often protects from CRC development. An important consideration in evaluating new drugs and devices is determining whether a product can effectively treat a targeted disease. There are a number of agents making their way into clinical trials by estimating their effects on biomarkers' expression. Also, some are awaiting the preclinical efficacy and safety results to enter into clinical trials. Oncologic researchers are facing challenges in modifying trial design and defining the right control population, validating biomarker assays from the biological and analytical perspective. However, the results are disappointing from many of the large clinical trials. To avoid these disappointments, selection of biomarkers and its target agents needs to be evaluated in appropriate animal models for their efficacies as well as toxicities. This review focuses on the few of the potential molecular targets and their biomarkers in CRC development.

show abstract

5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

Cited by 20 publications

References 46 publications

Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway

Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway

Matrix metalloproteinase‐2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer

Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets

Contact Info

Product

Resources

About